Bogdan Nowakowski, MD
Pulmonary Disease · Gonzales, LANPI 1659476265
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 502 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 502 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- GSK$1K
- AbbVie$967
- Redhill Biopharma Inc.$899
- AstraZeneca$858
- Takeda Pharmaceuticals U.S.A., Inc.$757
- plus $5K from 29 others
What the payments were for
- Food & beverage$11,507100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 83 | $1,742 |
| GSK | 33 | $1,067 |
| AbbVie(2 entities) | 46 | $967 |
| Redhill Biopharma Inc. | 43 | $899 |
| AstraZeneca | 25 | $858 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $757 |
| Ironwood Pharmaceuticals, Inc | 39 | $670 |
| Ardelyx, Inc. | 19 | $494 |
| Boehringer Ingelheim | 14 | $408 |
| Johnson & Johnson | 23 | $365 |
| Gilead | 4 | $349 |
| Ipsen Biopharmaceuticals, Inc | 15 | $341 |
| Merck | 20 | $292 |
| Phathom Pharmaceuticals, Inc. | 17 | $283 |
| QOL Medical, LLC | 14 | $278 |
| Madrigal Pharmaceuticals | 9 | $220 |
| Braintree Laboratories, Inc. | 10 | $197 |
| Intercept Pharmaceuticals, Inc. | 5 | $196 |
| Sanofi | 3 | $174 |
| Regeneron Healthcare Solutions, Inc. | 3 | $149 |
| Paratek Pharmaceuticals, Inc. | 7 | $130 |
| Shionogi Inc | 7 | $128 |
| Pulmonx Corporation | 1 | $92 |
| Insmed, Inc. | 4 | $80 |
| Genentech USA, Inc. | 1 | $72 |
| Viatris Specialty LLC | 4 | $70 |
| Mylan Specialty L.p. | 3 | $66 |
| Romark Laboratories, LC | 3 | $44 |
| Baxter Healthcare | 2 | $39 |
| Circassia Inc. | 2 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Valinor Pharma, LLC | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| CSL Behring | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$345
- TRELEGY ELLIPTA$244
- BREZTRI$206
- Epclusa$127
- VIBERZI$125
- OCALIVA$123
- AREXVY$123
- DUPIXENT$122
- Entyvio$118
- BREZTRI AEROSPHERE$109
How this compares
$11,537 in reported general payments places this provider in the 75th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 137 | $106,815 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 110 | $60,727 |
| Spiriva RespimatTiotropium Bromide | 72 | $41,116 |
| Spiriva HandihalerTiotropium Bromide | 49 | $31,331 |
| SymbicortBudesonide/Formoterol Fumarate | 98 | $27,000 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $24,664 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $21,641 |
| OzempicSemaglutide | 14 | $17,743 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 538 | $14,904 |
| LinzessLinaclotide | 21 | $11,101 |
| Atrovent HfaIpratropium Bromide | 19 | $8,834 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $7,836 |
| Theophylline ErTheophylline Anhydrous | 126 | $7,217 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,735 |
| Arnuity ElliptaFluticasone Furoate | 15 | $4,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,067 | $165,335261 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $408 | $107,578194 claims |
| AstraZenecaSymbicort | $858 | $27,00098 claims |
| AbbVieLinzess | $967 | $11,10121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Gonzales
- Gretchen YandleGonzales$11K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- Charles GbadouweyMonroe$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.